Application of lenalidomide to preparing medicine for relieving multiple sclerosis

A technology for multiple sclerosis and lenalidomide, which can be used in drug combinations, pharmaceutical formulations, allergic diseases, etc., and can solve problems such as lack of protection against multiple sclerosis

Inactive Publication Date: 2015-12-30
ZHEJIANG UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far there is no report on its protective effect on multiple sclerosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of lenalidomide to preparing medicine for relieving multiple sclerosis
  • Application of lenalidomide to preparing medicine for relieving multiple sclerosis
  • Application of lenalidomide to preparing medicine for relieving multiple sclerosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] 50 C57BL / 6 adult female mice were used to make the EAE model. First, the mice were randomly divided into 6 groups, blank control group, EAE model group, EAE model group + lenalidomide low-dose administration group, EAE model group + lenalidomide There were 10 rats in each group of middle-dose lenalidomide administration group and EAE model group+lenalidomide high-dose administration group. Build EAE model: MOG first 35-55 Dissolve in sterile 1×PBS, the preparation concentration is 2mg / ml, dissolve Myco.Tuberculosis in complete Freund's adjuvant (CFA), the preparation concentration is 4mg / ml, vortex and mix. Then the two are mixed evenly by pumping and pushing back and forth through the syringe to prepare evenly dispersed immune antigens. Finally, 100 μl of the immune antigen was subcutaneously injected into the neck of the mouse, 50 μl of the immune antigen was injected subcutaneously into each of the left and right hind legs of the mouse, and 200 ng of pertussis toxin...

Embodiment 2

[0028] The spinal cords of each group on Day 23 were taken, frozen sections, and immunofluorescence. ⑴Take out the frozen section and dry it for 20 minutes; ⑵Wash 3 times with 1×PBS, 5 minutes each time; ⑶Blocking (1×PBS+5%NGS+0.3%Triton-100) for 1 hour; Preparation); (5) Wash 3 times with 1×PBS, 5 minutes each time; (6) Incubate with secondary antibody for 1 hour at room temperature in the dark (prepared with blocking buffer); (7) DAPI staining at room temperature for 5 minutes (in the dark); (8) Wash 3 times with 1×PBS, 5 minutes each time (protect from light); ⑼Seal the slide with antifade agent and store in the dark.

Embodiment 3

[0030] Paraffin-embedded the spinal cord and cross-sectioned the spinal cord with a thickness of 3 μm, and then stained with hematoxylin-eosin (Hematoxylin-Eosinstaining). ⑴ Dewax the paraffin sections with environmental transparent agent I for 15 minutes and environmental transparent agent II for 12 minutes; ⑷Stain in hematoxylin for about 2.5 minutes, rinse with tap water for about 15 minutes; ⑸Put the slices in 0.5% hydrochloric acid ethanol for color separation, see that the slices turn red, and the color is lighter; ⑹Wash for 5 minutes, ammonia water turns blue; ⑺Gradient dehydration , 70% ethanol for 2 minutes, 80% ethanol for 2 minutes, 90% ethanol for 2 minutes, 90% ethanol for 2 minutes; 95% ethanol for 2 minutes; Seal the slides after the agent is transparent.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of lenalidomide to preparing medicine for relieving multiple sclerosis. The lenalidomide is a derivative of thalidomide and is clinically mainly used for treating myelodysplastic syndromes, multiple myeloma and the like at present. As proved by in-vivo and in-vitro experimental research, the application has the advantages that obvious protection effects can be realized by the lenalidomide for EAE (experimental autoimmune encephalomyelitis) mice suffering from inflammatory demyelination induced by M. Tuberculosis (4 mg/ml), MOG35-55(myelin oligodendrocyte glycoprotein 35-55) (2 mg/ml) and Pertussis toxin (200 ng per mouse), and accordingly the lenalidomide can be applied to treating the multiple sclerosis.

Description

technical field [0001] The invention belongs to the field of pharmacy and relates to the application of chemical drug lenalidomide in the preparation of drugs for alleviating multiple sclerosis. Background technique [0002] Multiple sclerosis (Multiple Sclerosis) is the most common clinical demyelinating disease of the central nervous system, mainly in young adults, and mostly in women. Multiple sclerosis is highly prevalent among people in northern Europe and North America, with an incidence rate of 50-100 / 100,000, and the incidence rate in China is increasing year by year. Multiple sclerosis has rapid progression, high disability, poor treatment effect, and poor prognosis, which seriously affect the quality of life of patients. The animal model for simulating multiple sclerosis in the laboratory is the Experiment Allergic Encephalomyelitis model (EAE model for short). Current studies suggest that there are two main aspects to the pathogenesis of multiple sclerosis: on t...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/454A61P25/00A61P37/02
Inventor 翁勤洁王静谭笔琴王佳佳胡燕赵梦婷张卉盛荣杨波何俏军
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap